Abstract:Background: Locally advanced rectal cancer (LARC) patient stratification by clinicoradiologic factors may yield variable results. Therefore, more efficient prognostic biomarkers are needed for improved risk stratification of LARC patients, personalized treatment, and prognostication. Purpose/Hypothesis: To compare the ability of a radiomic signature to predict disease-free survival (DFS) with that of a clinicoradiologic risk model in individual patients with LARC. Study Type: Retrospective study. Population: In all, 108 consecutive patients (allocated to a training and validation set with a 1: 1 ratio) with LARC treated with neoadjuvant chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). Field Strength/Sequence: Axial 3D LAVA multienhanced MR sequence at 3T. Assessment: ITK-SNAP software was used for manual segmentation of 3D pre-nCRT MR images. All manual tumor segmentations were performed by a gastrointestinal tract radiologist, and validated by a senior radiologist. The clinicoradiologic risk factors with potential prognostic outcomes were identified in univariate analysis based on the Cox regression model for the whole set. The results showed that ypT, ypN, EMVI, and MRF were potential clinicoradiologic risk factors. Interestingly, only ypN and MRF were identified as independent predictors in multivariate analysis based on the Cox regression model. Statistical Tests: A radiomic signature based on 485 3D features was generated using the least absolute shrinkage and selection operator (LASSO) Cox regression model. The association of the radiomic signature with DFS was investigated by Kaplan-Meier survival curves. Survival curves were compared by the log-rank test. Three models were built and assessed for their predictive values, using the Harrell concordance index and integrated time-dependent area under the curve. Results: The novel radiomic signature stratified patients into low-and high-risk groups for DFS in the training set (hazard ratio [HR] =6.83; P < 0.001), and was successfully validated in the validation set (HR=2.92; P < 0.001). The model combining the radiomic signature and clinicoradiologic findings had the best performance (C index=0.788, 95% confidence interval [CI] 0.72-0.86; integrated time-dependent area under the curve of 0.837 at 3 years). Data Conclusion: The novel radiomic signature could be used to predict DFS in patients with LARC. Furthermore, combining this radiomic signature with clinicoradiologic features significantly improved the ability to estimate DFS (P=0.001, 0.005 in training set and in validation set, respectively), and may help guide individualized treatment in such patients.

LC–MS metabolomics analysis of serum metabolites during neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Ultra-Performance Liquid Chromatography Coupled with Quadrupole Time-Of-Flight Mass Spectrometry-Based Metabolic Profiling of Human Serum Prior to and Following Radical Resection of Colorectal Carcinoma

Changes of Serum Metabolites Levels During Neoadjuvant Chemoradiation and Prediction of the Pathological Response in Locally Advanced Rectal Cancer

Predicting the Pathological Response to Neoadjuvant Chemoradiation Using Untargeted Metabolomics in Locally Advanced Rectal Cancer.

Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer

LC–MS-based serum metabolomics analysis for the screening and monitoring of colorectal cancer

Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS.

Urinary metabonomic study on colorectal cancer.

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Multiparametric MRI-based radiomic model for predicting lymph node metastasis after neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Metabolomic Comparison of Patients With Colorectal Cancer at Different Anticancer Treatment Stages

Data-Independent Acquisition Mass Spectrometry Analysis of FFPE Rectal Cancer Samples Offers In-Depth Proteomics Characterization of the Response to Neoadjuvant Chemoradiotherapy

Comparing Neoadjuvant Long-Course Chemoradiotherapy with Short-Course Radiotherapy in Rectal Cancer

Metagenomic analysis reveals effects of gut microbiome in response to neoadjuvant chemoradiotherapy in advanced rectal cancer

Proteomic and metabolomic signatures of rectal tumor discriminate patients with different responses to preoperative radiotherapy

Prospective, longitudinal analysis of the gut microbiome in patients with locally advanced rectal cancer predicts response to neoadjuvant concurrent chemoradiotherapy

Characterization of the Tumor Microenvironment and Identification of Spatially Predictive Biomarkers Associated with Beneficial Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

80MO Gut Microbiome Analysis for Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Patients

Metagenomic Analysis of Intratumoral Microbiome Linking to Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer

Novel Radiomic Signature As a Prognostic Biomarker for Locally Advanced Rectal Cancer.

47P Safety and Efficacy Evaluation of Long-Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Total Mesorectal Excision for Locally Advanced Rectal Cancer: Intermediate Results of a Multicenter, Phase II Study